 SANTA MONICA, Calif., Feb. 08, 2021 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT today announced the dosing of the first patient in a confirmatory pharmacokinetic PK study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021. 